Updated 18 October 2026 | Dubai & United Arab Emirates

Weight loss medications in Dubai and across the UAE have changed significantly during 2026. Patients considering prescription medical weight management now have more treatment options, including established weekly injections and newly approved daily weight-loss tablets.
Mounjaro and Wegovy remain two of the best-known prescription treatments. However, the arrival of Wegovy Pill (oral semaglutide) and Foundayo (orforglipron) has expanded the choices available to patients who would prefer an oral alternative.
Other medicines familiar to Dubai patients, particularly Ozempic and Rybelsus, also contain semaglutide. However, these are primarily diabetes treatments and are not interchangeable with medicines specifically approved for weight management.
So which weight-loss medication is most effective? How much weight can patients realistically lose? Are tablets as effective as injections? And what should someone living in Dubai consider before beginning treatment?
This comprehensive 2026 guide explains the principal prescription medicines available in the UAE, the differences between them, published clinical trial results, costs, safety considerations and how patients can explore medically supervised treatment.
What’s Changed for Weight Loss Medications in the UAE in 2026?
The most important developments during 2026 have been the introduction of new oral GLP-1 treatments alongside established injectable medicines.
April 2026: Foundayo Approved in the UAE
On 3 April 2026, the Emirates Drug Establishment announced approval of Foundayo (orforglipron), developed by Eli Lilly.
Foundayo is a once-daily oral GLP-1 receptor agonist approved for chronic weight management.
The UAE became the second country globally to register the treatment.
Unlike oral semaglutide, Foundayo does not have the same specific restrictions concerning food and water when taking the tablet.
This offers another option for eligible patients seeking medically supervised weight reduction without injections.
June 2026: Wegovy Pill Launches in Dubai and the UAE
On 1 June 2026, the Emirates Drug Establishment announced approval of Wegovy Pill (oral semaglutide) for long-term weight management in eligible adults.
Novo Nordisk subsequently announced the UAE launch on 3 June 2026.
The UAE became the first market outside the United States to launch Wegovy Pill.
The significance is that semaglutide, already established through weekly Wegovy injections, can now also be prescribed in a dedicated daily tablet formulation.
For patients researching weight loss pills in Dubai, this represents a substantial development.
Both medicines are prescription treatments and require individual clinical assessment. Local pharmacy supply and suitability must be confirmed.
Which Weight Loss Medications Are Available in Dubai?
Six commonly discussed medications are particularly relevant when researching modern GLP-1 treatments in the UAE.
These include three weekly injections and three daily tablets.
Weekly injections
Mounjaro (tirzepatide) A dual GIP and GLP-1 receptor agonist used in medically supervised weight-management treatment.
Wegovy injection (semaglutide) A GLP-1 receptor agonist specifically indicated for weight management.
Ozempic (semaglutide) A weekly injection primarily indicated for type 2 diabetes, although weight loss can occur during treatment.
Daily tablets
Wegovy Pill (oral semaglutide) A once-daily semaglutide formulation specifically approved for weight management.
Foundayo (orforglipron) A newer once-daily oral GLP-1 treatment approved for chronic weight management.
Rybelsus (oral semaglutide) An established oral semaglutide medicine primarily indicated for type 2 diabetes.
Although several medicines share similar mechanisms or the same active ingredient, they differ in formulation, approved indication, administration, dose and clinical evidence.

1. Mounjaro (Tirzepatide) — Weekly Weight Loss Injection
Mounjaro has become one of the most widely discussed prescription weight-loss treatments in Dubai.
It contains tirzepatide, which activates two hormone receptors involved in appetite and metabolic regulation: GIP and GLP-1.
By influencing these pathways, Mounjaro can help reduce hunger, increase fullness and support reduced food intake.
It is administered as a once-weekly injection, with gradual dose escalation according to clinical suitability and tolerability.
How effective is Mounjaro?
In the landmark SURMOUNT-1 clinical trial, participants receiving tirzepatide 15 mg achieved an estimated 22.5% average reduction in starting body weight over 72 weeks, under the study’s efficacy analysis.
The corresponding average reduction in the analysis accounting for treatment discontinuation was 20.9%.
These are substantial clinical results, but they are not guaranteed outcomes.
Not every patient reaches the maximum dose, and individual progress depends on multiple factors, including medical history, tolerance, nutritional intake, physical activity and treatment duration.
Mounjaro must be prescribed following appropriate medical assessment.
Considering Mounjaro in Dubai?
Explore Allure’s Mounjaro weight loss programme in Dubai, including the available levels of clinical and nutritional support.
2. Wegovy Injection (Semaglutide) — Weekly GLP-1 Treatment
Wegovy contains semaglutide, a GLP-1 receptor agonist that influences appetite and feelings of fullness.
Like Mounjaro, injectable Wegovy is administered once weekly, although the active ingredients and mechanisms are different.
Semaglutide can help eligible patients reduce food intake, improve portion control and achieve progressive weight reduction when combined with appropriate lifestyle intervention.
How effective is Wegovy injection?
In the STEP 1 clinical trial, adults receiving semaglutide 2.4 mg weekly achieved approximately 14.9% average weight loss over 68 weeks, compared with 2.4% for placebo.
The exact outcome for an individual patient will depend on clinical factors, adherence and treatment response.
Treatment usually starts at a low dose and increases gradually under medical supervision.
For patients who prefer a weekly treatment schedule, Wegovy remains an established option supported by substantial clinical research.
Learn more about Allure’s Wegovy injection programme in Dubai.
3. Wegovy Pill (Oral Semaglutide) — Daily Weight Loss Tablet
Wegovy Pill is one of the most significant new weight-management medications introduced in the UAE during 2026.
It contains semaglutide, the same active ingredient as the weekly Wegovy injection, but uses a specialised once-daily oral formulation.
This may appeal to patients in Dubai who dislike injections or prefer a tablet-based treatment.
However, oral Wegovy has specific administration requirements.
The tablet must be taken in the morning on an empty stomach with a limited amount of plain water. Patients must then wait at least 30 minutes before eating, drinking or taking other oral medicines, following the instructions for the prescribed product.
These requirements are important because they influence how effectively semaglutide is absorbed.
How effective is Wegovy Pill?
The OASIS 4 clinical trial investigated oral semaglutide 25 mg in adults with obesity, or overweight with a related health condition, without diabetes.
At 64 weeks:
- Average weight loss was 16.6% in the analysis assuming continued treatment.
- Average weight loss was 13.6% in the analysis including treatment discontinuation.
These results demonstrate that an oral weight-loss medicine can produce substantial weight reduction.
For a simple overview, the clinical evidence supports describing oral Wegovy as achieving approximately 14–17% average weight loss under different trial analyses.
However, these are study averages rather than predictions for individual patients.
Read more about Allure’s Wegovy Pill programme in Dubai.
4. Foundayo (Orforglipron) — New Daily Oral GLP-1 Treatment
Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist developed by Eli Lilly.
Although Foundayo and Wegovy Pill are both oral GLP-1 treatments, they are not the same medicine.
One important difference is how they are taken.
Foundayo does not require the same specific fasting and water restrictions as oral semaglutide.
This may make it more convenient for some patients who find strict morning medication routines challenging.
How effective is Foundayo?
In the ATTAIN-1 phase 3 clinical trial, participants receiving the highest studied dose achieved approximately 12.4% average weight loss over 72 weeks under the efficacy analysis.
The broader trial analysis accounting for treatment discontinuation showed approximately 11.2% average weight loss.
The study also found an approximately 11.5-percentage-point greater reduction than placebo under the efficacy analysis.
This last figure is the difference versus placebo, rather than the total average weight lost.
These findings demonstrate meaningful weight reduction with an oral medicine, although outcomes depend on the dose, duration, clinical suitability and individual response.
Foundayo received UAE approval in April 2026 and is part of the current range of available prescription weight-management medicines, subject to local supply and appropriate prescribing.
Foundayo is included here for patient education. Its inclusion does not mean that it is currently supplied through an Allure programme.
5. Ozempic (Semaglutide) — A Diabetes Medicine Associated With Weight Loss
Ozempic is a widely recognised prescription injection available in Dubai and the wider UAE.
It contains semaglutide, the same active ingredient found in Wegovy.
Ozempic is administered once weekly and is primarily indicated for type 2 diabetes.
Many patients taking Ozempic experience weight reduction, which explains its prominence in discussions about GLP-1 medication and obesity.
However, Ozempic and Wegovy are not identical treatment products.
They have different approved indications, dose pathways and prescribing information.
Patients should not assume that Ozempic can be substituted for Wegovy or that the two products should be prescribed in the same way.
For patients seeking medication specifically for obesity in Dubai, a clinician should consider appropriately indicated treatments and the individual’s overall medical circumstances.
6. Rybelsus (Oral Semaglutide) — How Does It Differ From Wegovy Pill?
Rybelsus is another oral medicine containing semaglutide.
It was available before Wegovy Pill and is primarily indicated for treating type 2 diabetes.
Because both medicines contain oral semaglutide, patients sometimes assume they are interchangeable.
They are not.
Rybelsus is not simply another brand name for Wegovy Pill.
The two products have different approved uses, dosing regimens and treatment objectives.
Rybelsus may influence body weight, but it should not automatically be regarded as equivalent to oral Wegovy’s dedicated weight-management formulation.
Patients already receiving Rybelsus for diabetes should never independently change to Wegovy Pill or attempt to convert doses between the products.
Any treatment change requires clinical review.
Other Prescription Weight Loss Medicines
There are also other medications used in weight management, including liraglutide-based treatments such as Saxenda and non-GLP-1 medicines such as orlistat.
Their effectiveness, suitability, administration and safety profiles differ from newer GLP-1 treatments.
The most appropriate medication depends on the patient’s medical circumstances rather than simply selecting the newest product.
How Much Weight Can You Lose With Weight Loss Medications in Dubai?
One of the most common questions asked by patients considering medical weight loss is how much weight they might realistically lose.
Modern prescription medicines have demonstrated substantial results in major clinical trials.
The following findings provide useful examples.
Mounjaro — Up to 22.5% Average Weight Loss
In SURMOUNT-1, participants receiving tirzepatide 15 mg achieved an estimated 22.5% average body-weight reduction at 72 weeks under the efficacy analysis.
This reflects the highest studied dose and the specified clinical trial analysis, not a result every patient can expect.
Wegovy Injection — Approximately 15% Average Weight Loss
In STEP 1, weekly injectable semaglutide 2.4 mg produced approximately 14.9% average weight loss at 68 weeks.
Wegovy Pill — Approximately 14–17% Average Weight Loss
In OASIS 4, daily oral semaglutide 25 mg achieved 16.6% average weight loss in the analysis assuming continued treatment and 13.6% when treatment discontinuation was included, at 64 weeks.
Foundayo — Approximately 11–12% Average Weight Loss
In ATTAIN-1, participants receiving the highest studied orforglipron dose achieved approximately 11.2% to 12.4% average weight loss at 72 weeks, depending on the analysis.
Can These Results Be Compared Directly?
Not necessarily.
The figures come from different clinical trials with different durations, participants, doses and statistical approaches.
They should not be treated as a direct ranking of every medicine.
A separate head-to-head study, SURMOUNT-5, directly compared tirzepatide and injectable semaglutide in adults with obesity without diabetes.
At 72 weeks, average weight loss was approximately 20.2% with tirzepatide and 13.7% with injectable semaglutide under that study’s reported analysis.
That is a direct comparison under the conditions of SURMOUNT-5, but it does not establish how every individual will respond.
The best medication is not automatically the one reporting the highest percentage.
The appropriate treatment must also consider safety, clinical suitability, tolerability, cost and longer-term weight-management planning.
Weight Loss Injections vs Tablets in Dubai: Which Is Better?
Following the arrival of Wegovy Pill and Foundayo, patients in Dubai have more choice between oral and injectable GLP-1 treatment.
However, the assumption that weight-loss injections are always more effective than tablets is no longer reliable.
Why Some Patients Prefer Weekly Injections
Weekly injections may suit people who prefer administering medication once a week rather than remembering a tablet every day.
Mounjaro and injectable Wegovy also have established clinical evidence and recognised treatment pathways.
Why Some Patients Prefer Daily Tablets
Oral treatment may appeal to patients who dislike needles or prefer a daily routine.
However, the differences between Wegovy Pill and Foundayo are important.
Oral Wegovy has specific fasting and administration requirements, while Foundayo has different instructions.
A tablet is not automatically easier or more appropriate for every patient.
The active medicine, administration requirements, clinical suitability and treatment goals should guide the decision.
For a detailed explanation, see our guide to oral weight loss medications versus injections.

Who Is Suitable for Weight Loss Medication in Dubai?
Prescription weight-management medicines are intended for patients who meet relevant clinical criteria.
For many obesity treatments, typical adult eligibility requirements include:
- A body mass index (BMI) of 30 or above.
- A BMI of 27 or above with a qualifying weight-related medical condition.
Examples of weight-related conditions can include hypertension, abnormal cholesterol and obstructive sleep apnoea.
The precise criteria depend on the medication and its approved prescribing information.
A medical assessment should consider more than BMI alone.
Relevant factors include:
- Current and previous medical conditions.
- Existing medication.
- Previous weight-loss treatment.
- Relevant contraindications.
- Diabetes and metabolic health.
- Pregnancy or pregnancy plans.
- Lifestyle and nutritional requirements.
- Longer-term weight-management goals.
Some patients already receiving medication may require a separate clinical review when discussing treatment continuation, maintenance or changes.
Meeting a BMI threshold does not automatically guarantee suitability.
Patients considering starting or reviewing treatment can explore Allure’s medical weight-loss programmes in Dubai.
How Much Do Weight Loss Medications Cost in Dubai?
The price of prescription weight-loss medication in Dubai varies according to the medicine, dose, supplier and level of clinical support.
Patients researching Mounjaro cost in Dubai, Wegovy price in Dubai or the cost of oral weight-loss medication should distinguish between the medicine itself and a medically supported programme.
Costs may depend on:
- The prescribed medicine.
- Dose and treatment duration.
- Pharmacy supply and availability.
- Medical consultations.
- Treatment monitoring and dose reviews.
- Dietitian and bariatric nurse support.
- Delivery and other programme inclusions.
A low advertised medication price does not necessarily include the clinical support that a patient may need.
Equally, not every patient requires the same intensity of follow-up.
At Allure, the available programmes provide different levels of support according to individual requirements.
Patients can explore the Core, Support and Premium pathways through Allure’s medical weight-loss programme overview.
Current pricing and programme inclusions should be confirmed directly because medication supply and pharmacy prices may change.
Are Weight Loss Medications Safe? Side Effects and Important Considerations
Modern GLP-1 medicines can provide significant benefits for appropriately selected patients, but they also carry risks.
Commonly reported side effects include:
- Nausea.
- Vomiting.
- Diarrhoea.
- Constipation.
- Abdominal discomfort.
- Indigestion and reflux.
- Reduced appetite.
Side effects may be more noticeable when treatment begins or after dose increases.
Many gastrointestinal symptoms improve over time, but persistent or severe symptoms require medical assessment.
Clinicians must also consider serious potential risks, including pancreatitis, gallbladder problems, severe gastrointestinal reactions and dehydration.
Patients taking insulin or certain diabetes medicines may require additional monitoring because of the risk of low blood glucose.
Relevant contraindications, medical and family history, pregnancy, breastfeeding and interactions with existing medication must be assessed before prescribing.
Product-specific restrictions differ and should be checked against current approved prescribing information.
Patients with severe persistent abdominal pain, serious allergic symptoms or significant dehydration should seek urgent medical attention.
Why Authentic Medication Supply Matters
Demand for weight-loss medication in Dubai has increased the importance of reliable pharmaceutical supply.
Patients should obtain prescription medication only through appropriately licensed clinicians and legitimate pharmacies.
They should avoid unverified products, informal online sellers and self-directed changes to prescribed medication.
Different GLP-1 products should not be combined or substituted without the prescribing clinician’s direction.
Medical supervision is essential for managing side effects, reviewing progress and ensuring that the treatment remains appropriate.
What Happens When You Stop Mounjaro or Wegovy?
One of the most important questions before starting prescription weight-loss medication concerns what happens after treatment.
GLP-1 medicines influence appetite and eating behaviour while they are being used.
When treatment stops, appetite may increase again, and some patients experience weight regain.
Clinical research has demonstrated that weight regain following semaglutide withdrawal can be substantial.
This does not mean that every patient must remain on the same medicine or dose permanently.
However, long-term planning should be discussed from the beginning.
Nutrition, physical activity, resistance exercise, behavioural support and appropriate follow-up all contribute to a sustainable weight-management strategy.
Patients considering reducing, stopping or changing medication should discuss their circumstances with the prescribing clinician.
Read our dedicated guide: What Happens When You Stop Mounjaro or Wegovy? Weight Regain and Maintenance in Dubai.
What Other Weight Loss Treatments Are Available in Dubai?
Weight-loss medication is not the only medical treatment available for obesity.
Some patients may be unable to tolerate medication, have contraindications, prefer not to use ongoing prescription treatment or require a different clinical approach.
Depending on suitability, other options include:
Gastric balloons
Temporary, non-surgical weight-loss devices designed to support portion control and reduced food intake.
Allure offers different balloon programmes, including swallowable and endoscopic options, according to clinical suitability.
Endoscopic weight-loss procedures
Procedures such as endoscopic sleeve gastroplasty may be considered for selected patients, subject to clinical assessment and confirmed provider availability.
Bariatric surgery
Procedures including gastric sleeve and gastric bypass may be appropriate for patients meeting relevant surgical criteria.
These approaches differ substantially in invasiveness, expected results, recovery and long-term requirements.
Patients can explore gastric balloon treatment in Dubai or discuss the broader treatment pathways with Allure’s coordination team.
Not sure which weight-loss pathway to explore? Our 360° Treatment Finder brings together medication, gastric balloons and bariatric surgery in one personalised educational guide. See how published research translates into kilograms at your starting weight and compare indicative Dubai treatment costs before speaking with our team.
Explore your options with the Treatment Finder
What’s Next for Weight Loss Medications Beyond 2026?
Research into obesity medication continues to progress rapidly.
Investigational compounds and combinations, including retatrutide, CagriSema and amycretin, are being studied for their potential role in future weight-management treatment.
Some aim to influence multiple appetite and metabolic pathways, while others are being developed with different administration schedules.
Promising clinical trial results do not automatically mean a medicine is approved or commercially available in the UAE.
Patients should distinguish between investigational medicines, approved treatments and products currently obtainable through licensed local healthcare providers.
For patients seeking weight-management treatment now, understanding established and newly approved options remains the most useful starting point.
Frequently Asked Questions About Weight Loss Medications in Dubai
Which weight loss medications are available in Dubai in 2026?
Relevant prescription weight-management treatments include Mounjaro, Wegovy injection, Wegovy Pill and Foundayo. Ozempic and Rybelsus are also available as semaglutide medicines primarily indicated for type 2 diabetes. Individual suitability and current pharmacy supply must be confirmed.
Can I get weight loss pills in Dubai?
Yes. Wegovy Pill and Foundayo are oral GLP-1 treatments approved for eligible patients requiring weight management. They are prescription medicines and require clinical assessment.
Is Wegovy Pill as effective as injections?
Oral Wegovy has demonstrated substantial weight loss in clinical trials. In OASIS 4, average weight reduction reached 16.6% under the analysis assuming treatment adherence. However, comparisons between different medicines and trials require care.
How much weight can I lose with Mounjaro?
In SURMOUNT-1, tirzepatide 15 mg produced an estimated 22.5% average weight loss over 72 weeks under the efficacy analysis. Individual results vary, and not everyone reaches or requires the highest dose.
Is Foundayo better than Wegovy Pill?
Both are oral GLP-1 treatments but contain different active ingredients and have different administration requirements. Their suitability depends on the individual patient. Results from separate trials should not be interpreted as direct proof that one is universally better.
Is Ozempic the same as Wegovy?
Both contain semaglutide, but Ozempic is primarily a diabetes medicine, whereas Wegovy has specific weight-management indications. Their approved uses and dose pathways differ.
Is Rybelsus the same as Wegovy Pill?
No. Both contain oral semaglutide, but they are different products with different approved indications and dosing regimens. They should not be substituted without clinical direction.
Can I switch from Mounjaro to Wegovy or an oral medication?
A change may be suitable for some patients, but it requires a clinical review. Dose equivalence, timing, previous treatment and relevant medical risks must be considered by the prescribing doctor.
Which is better for weight loss, Mounjaro or Wegovy?
In SURMOUNT-5, tirzepatide produced greater average weight loss than injectable semaglutide under that study’s conditions. However, the most appropriate treatment for an individual patient also depends on clinical suitability, safety, tolerability and preferences.
Will I regain weight if I stop GLP-1 treatment?
Weight regain can occur after medication is stopped. The degree varies between patients. A longer-term maintenance plan should be discussed before stopping or changing treatment.
Do I need a medical assessment to receive weight-loss medication in Dubai?
Yes. Prescription treatment requires appropriate clinical assessment and prescribing by a licensed clinician. Patients should avoid informal or unverified suppliers.
Considering Weight Loss Medication in Dubai?
The introduction of new oral GLP-1 treatments has expanded the options available to patients across Dubai and the UAE.
Mounjaro, Wegovy injections, Wegovy Pill and Foundayo offer different treatment characteristics. Ozempic and Rybelsus also remain relevant medicines to understand because of their role in diabetes treatment and association with weight reduction.
But having more treatment choices does not remove the need for individual medical assessment.
The right weight-management approach should reflect your medical history, treatment goals, preferences and longer-term health needs.
Allure Weightloss specialises in medical weight management for people living in Dubai and across the UAE.
Our programmes combine treatment coordination, appropriate medical assessment and ongoing support, with prescribing decisions and clinical treatment delivered by licensed UAE professionals.
Whether you’re considering weight-loss medication for the first time, reviewing an existing treatment or exploring long-term weight maintenance, our team can help you understand your options.
Explore Allure’s Medical Weight Loss Programmes in Dubai →
Medical disclaimer: This article is provided for general educational purposes only and does not replace individual medical advice. Prescription medicines must be used under appropriate clinical supervision. Medication availability, approved indications and prescribing requirements may change.
Medical and Regulatory References
- Emirates Drug Establishment — Foundayo approval, 3 April 2026
- Emirates Drug Establishment — Oral Wegovy approval, 1 June 2026
- SURMOUNT-1 — Tirzepatide Once Weekly for the Treatment of Obesity, NEJM
- STEP 1 — Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM
- OASIS 4 — Oral Semaglutide 25 mg for Obesity, NEJM
- ATTAIN-1 — Orforglipron for Obesity Treatment, NEJM
- SURMOUNT-5 — Tirzepatide versus Semaglutide for Obesity, NEJM
- Novo Nordisk UAE — Professional Product Information
- STEP 1 Extension — Weight Regain After Semaglutide Withdrawal